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Cyclic nucleotides (cAMP and cGMP) are the main second messengers linked to vasodilatation. They are synthesized by cyclases and
degraded by different types of phosphodiesterases (PDE). The effect of PDE inhibition and cyclases stimulation on 5-hydroxytryptamine (5-HT;
1 μM) and histamine (10 μM) contracted arteries was analysed. Stimulation of guanylate cyclase or adenylate cyclase relaxed the histamine- and
5-HT-induced contractions indicating that intracellular increase of cyclic nucleotides leads to vasodilatation of the human umbilical artery. We
investigated the role of different PDE families in the regulation of this effect. The presence of the different PDE types in human umbilical artery
smooth muscle was analysed by RT-PCR and the expression of PDE1B, PDE3A, PDE3B, PDE4C, PDE4D and PDE5A was detected. The
unspecific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX; 50 μM) relaxed histamine-contracted human umbilical artery on 47.4±7.2%. This
effect seems to be due to PDE4 and PDE5 inhibition because among the selective PDE inhibitors used only the PDE4 inhibitor (rolipram; 1 μM)
and the PDE5 inhibitors (dipyridamole and T0156; 3 μM and 1 μM respectively) induced significant relaxation (39.0±8.7, 30.4±6.0 and 36.3±
2.8 respectively). IBMX, dipyridamole and T0156 produced similar relaxation on 5-HT-induced contraction. After forskolin, the addition of
IBMX or rolipram increased the effect of the adenylate cyclase stimulator and almost completely relaxed the human umbilical artery contracted by
histamine (92.5±4.9 and 90.9±4.7 respectively), suggesting a main role of PDE4. The data obtained with 5-HT contracted arteries confirmed this,
because only rolipram and IBMX significantly increased the forskolin vasodilator effect. The administration of dipyridamole and T0156 after
sodium nitroprusside (SNP) induced a significant increase of the SNP relaxant effect on histamine-contracted arteries, but PDE1 and PDE3
inhibition did not increase the effect of the guanylate cyclase stimulator. Similar effects were obtained in 5-HT contracted arteries, the SNP
induced relaxation was increased by the PDE5 inhibition, but not by PDE1 or PDE3 inhibition. In summary, our results demonstrate that: 1) the
increase of cAMP and/or cGMP levels induces relaxation of the human umbilical vascular smooth muscle; 2) four families of PDE are expressed
in this smooth muscle: PDE1, PDE3, PDE4 and PDE5; 3) between these families, PDE4 and PDE5 are the key enzymes involved in the regulation
of the relaxation associated to cAMP and cGMP, respectively.
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Human umbilical artery is involved in fetoplacental circula-
tion. The mechanisms that regulate the contractile state of this
artery are very important for optimum gas and nutrient exchange
between the foetus and the placenta. Since the umbilical blood⁎ Corresponding author. Tel.: +351 275 329049; fax: +351 275 329099.
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doi:10.1016/j.ejphar.2007.12.017vessels are not innervated, the control of umbilical blood flow
depends entirely on vasoactive substances either released locally
or existing in the circulation (Leung et al., 2006). The un-
derstanding of the intracellular mechanisms modulating human
umbilical artery contractility may offer therapeutic value for the
treatment of some pathologies as pre-eclampsia. Cyclic nucleo-
tides (cAMP and cGMP) are the main second messengers linked
to vasodilatation. The intracellular levels of these second messen-
gers are regulated by adenylate cyclase and guanylate cyclase,
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terases (PDEs), involved in their hydrolysis (Lugnier, 2006;
Rybalkin et al., 2003; Tilley and Maurice, 2002). Because the
PDE isoenzymes are differentially expressed and regulated, they
were considered good targets for therapeutic intervention for
cardiovascular diseases (Matsumoto et al., 2003; Rybalkin et al.,
2003), but additional knowledge is necessary to achieve this
point. Concerning the fetoplacental circulation, cyclic nucleotides
increase was appointed as beneficial because it dilates the arteries,
enhances placental oxygen uptake alleviating hypoxemic fetal
stress and ameliorates the fetal nutrition resumes (Downing et al.,
2004). In this sense, nitrovasodilators were already suggested for
the treatment of hypertension in pregnancy (Amit et al., 1998).
To date, at least 11 different families of PDE isozymes have
been identified, which are further differentiated into 24 subfami-
lies with various splice variants (Gupta et al., 2005; Lugnier,
2006; Matsumoto et al., 2003). The PDE isozymes described as
being expressed in distinct types of vascular smooth muscle are
PDE1, PDE3, PDE4 and PDE5 (Maurice et al., 2003; Noguera
et al., 2001; Rybalkin et al., 2003). PDE2 and PDE7 transcripts
were only detected in porcine aorta smoothmuscle and in human
pulmonary artery respectively (Matsumoto et al., 2003).
These PDEs families differ in their regulation and substrate
specificity (cAMP or cGMP) (Lugnier, 2006; Matsumoto et al.,
2003). PDE1 is a Ca2+-calmodulin-activated PDE which hydro-
lyses cAMP and cGMP (Beavo, 1995; Lugnier, 2006). Three
different PDE1 gene products have been cloned (PDE1A, PDE1B
and PDE1C). PDE1A and PDE1B hydrolyse cGMP more effi-
ciently than cAMP (Beavo, 1995) and have been identified in
several vascular smooth muscles (Matsumoto et al., 2003).
PDE1C hydrolyses cAMP and cGMPwith equal efficiency but is
only expressed in cultured smooth muscle cells and its function is
relevant for cell proliferation (Maurice et al., 2003; Noguera et al.,
2001; Rybalkin et al., 2003). PDE2 is encoded by a unique gene
and is a cGMP-stimulated PDE which hydrolyses cAMP and
cGMP (Gupta et al., 2005; Lugnier, 2006; Matsumoto et al.,
2003). PDE3 is a cGMP-inhibited PDE which hydrolyses cAMP
with a rate 10-fold greater than for cGMP hydrolysis, but this
enzyme has a greater affinity for cGMP (Beavo, 1995; Gupta
et al., 2005; Lugnier, 2006). At present, two genes of this family
were described: PDE3A and PDE3B and products of both genes
were identified in the several vascular smoothmuscle cells (Gupta
et al., 2005; Lugnier, 2006). PDE4 hydrolyses selectively cAMP
with high affinity and is specifically inhibited by rolipram (Gupta
et al., 2005; Lugnier, 2006; Matsumoto et al., 2003). PDE4 is
currently the largest family of PDEs and products of four different
genes are known (PDE4A, PDE4B, PDE4C and PDE4D) (Gupta
et al., 2005; Lugnier, 2006). PDE5 specifically hydrolyses cGMP
with high affinity (Matsumoto et al., 2003). High levels of PDE5
were found in several smoothmuscles, including vascular smooth
muscle (Gupta et al., 2005). To date, only one gene has been
reported for this family (PDE5A) (Gupta et al., 2005). PDE7
specifically hydrolyses cAMP with high affinity (Matsumoto
et al., 2003). In humans and mice, two genes (PDE7A and
PDE7B) have been identified (Matsumoto et al., 2003).
The increase in the intracellular levels of cyclic nucleo-
tides by cyclases stimulation or by PDEs inhibition represents auseful strategy to study their biological effects. Relaxation of
vascular smooth muscle induced by PDE inhibitors was de-
scribed by several authors. Some authors indicated that PDE1
and PDE3 play an important role modulating the contractility of
rat aorta (Noguera et al., 2001) and other observed that PDE5
inhibition induces direct relaxation of this artery (Mochida
et al., 2002a). Lillestll et al. (1998) demonstrated that PDE3 was
the main enzyme regulating the cGMP-relaxant effect in porcine
coronary artery (Lillestll et al., 1998). Willette et al. suggested
that PDE4 is the predominant family implicated in the cAMP-
dependent regulation of the canine basilar artery contractility
(Willette et al., 1997). Waldkirch et al. observed that cAMP-
dependent relaxation is mediated by PDE3 and PDE4 and PDE5
is the main family modulating the vasodilatation associated to
cGMP in human cavernous arteries (Waldkirch et al., 2005).
The involvement of PDE3 and PDE5 in the modulation of
cGMP-dependent relaxation was also observed in human pul-
monary artery (Rabe et al., 1994). Due to the cGMP effects in
fetoplacental circulation, some authors proposed the use of
nitrovasodilators or PDE5 inhibitors for pregnant women with
vascular complications (Amit et al., 1998; Downing et al., 2004;
Pinheiro da Costa et al., 2006). Furthermore, nitric oxide (NO)
and sodium nitroprusside (NO donor) were shown to induce
relaxation of the human umbilical artery (Lovren and Triggle,
2000). This biological action of NO can be attributed to the
stimulation of soluble guanylate cyclase and the subsequent
production of cGMP (Lovren and Triggle, 2000).
The purpose of the present study was to investigate the
involvement of the cyclic nucleotides (cAMP and cGMP) and
PDEs in the mechanisms of human umbilical artery relaxation.
We investigated the expression of different PDE isoforms in
smooth muscle layers of this artery. The effects of several PDE
inhibitors, either alone and in the presence of adenylate cyclase
or guanylate cyclase stimulators, on the contractions induced by




Umbilical cord pieces of 3–7 cm were obtained from normal
term pregnancies with the consent of the donor mothers. All
procedures carried out with these samples were approved by
the Ethics Committee of “Centro Hospitalar da Cova da Beira
EPE”. The umbilical cord samples were collected in sterile phy-
siological saline solution (composition, mM: NaCl 110; CaCl2
0.15; KCl 5; MgCl2 2; HEPES 10; NaHCO3 10; KH2PO4 0.5;
NaH2PO4 0.5; Glucose 10; EDTA 0.49). In order to avoid con-
tamination and tissue degradation, penicillin (5 U/ml), strepto-
mycin (5 μg/ml), amphotericin B (12.5 ng/ml) and antiproteases
(leupeptine, 0.45 mg/l; benzamidine, 26 mg/l; and trypsin
inhibitor, 10 mg/l) were added to the physiological saline solu-
tion. Umbilical artery rings of 3–5 mm were isolated from the
surrounding connective tissue. Vascular endothelium was me-
chanically removed by gentle rubbing with a cotton bud intro-
duced through the arterial lumen. Some rings were chopped to
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tunica media of the artery were extracted using surgical forceps
and scalpel. The reverse transcriptase PCR experiments were
performed using RNA extracted from these samples.
2.2. PDEs expression analysis by reverse transcriptase PCR
Reverse transcriptase protein chain reaction (RT-PCR) by
using primers against the different PDE isoforms was used to
analyse their expression. The human housekeeping gene glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was used to
assess relative quantities of DNA from each sample.
Total RNA was prepared from smooth muscle layers of
human umbilical artery using the Tri reagent™ RNA purifi-
cation system (Sigma, Saint Louis, USA). The cDNA was
prepared from mRNA with random primers (3 μg/μl) using
Superscipt™ II RNAase H-reverse transcriptase and the con-
ditions recommended by the manufacturer (10 U/μl). Five ng of
cDNA was amplified in 25 μl reaction mixture containing
200 μM dNTPs, 0.625 U of Taq polymerase and 25 pmol/ml of
primers in the buffer supplied by the manufacturer (Promega,
Madison, USA). Oligonucleotide primers designed were as
follows:
PDE1A (Genbank accession number U40370): Forward
primer 5′-gtccctgattctccacgcagcag-3′, reverse primer 5′-tggt
ggttgagctgcttgccac-3′, fragment size 314 bp.
PDE1B (Genbank accession number AJ401609): Forward
primer 5′-tctgctccaagggagcgtggtc-3′, reverse primer 5′-tgc
cagctaagatctggggtgg-3′, fragment size 366 bp.
PDE2A (Genbank accession number U67733): Forward
primer 5′-gtggagaagcataccctggtcg-3′, reverse primer 5′-ggag
attgtcctccgacaccagc-3′, fragment size 280 bp.
PDE3A (Genbank accession number M91667): Forward
primer 5′-tgatcgccttgactagcgcggtc-3′, 5′-tccctcggtatacaggg
cagg-3′, fragment size 316 bp.
PDE3B (Genbank accession number U38178): Forward
primer 5′-tgctgagctgcgtagggctgctg-3′, reverse primer 5′-
actgccatagtaactggctgcag-3′, fragment size 332 bp.
PDE4A (Genbank accession number L20965): Forward
primer 5′-tctgtcagcgagatggcctcg-3′, reverse primer 5′-ggct
gttatggtaggccacgtc-3′, fragment size 550 bp.
PDE4B (Genbank accession number L20966): Forward
primer 5′-tccaagcgagcaacacggcgatg-3′, reverse primer 5′-tga
gaggtgtgtcagctcccggt-3′, fragment size 322 bp.
PDE4C (Genbank accession number Z46632): Forward
primer 5′-tcagttggagacgctgcagacc-3′, reverse primer 5′-gta
ggccactgatccgggacatg-3′, fragment size 227 bp.
PDE4D (Genbank accession number L20970): Forward
primer 5′-accagaaactggccagcgagac-3′, reverse primer 5′-aga
gagatgggtgagctcccga-3′, fragment size 143 bp.
PDE5A (Genbank accession number AF043731): Forward
primer 5′-gacatgtggcagcgcttggtg-3′, reverse primer 5′-agca
aggtcaagcagcacctga-3′, fragment size 320 bp.
PDE7A1 (Genbank accession number L12052): Forward
primer 5′-ggcagggcgggcgtattca-3′, reverse primer 5′-catgg
cctgagtaacatccgc-3′, fragment size 690 bp.PDE7A2 (Genbank accession number U67932): Forward
primer 5′-attgatctggtgtctggccttgg-3′, reverse primer 5′-catgg
cctgagtaacatccgc-3′, fragment size 582 bp.
GAPDH (Genbank accession number AF261085): Forward
primer 5′-tgaaggtcggagtcaacggatttggt-3′, reverse primer 5′-
catgtgggccatgaggtccaccac-3′, fragment size 983 bp.
The PCR procedures were performed as follows: 30 cycles
(30 s at 94 °C, 30 s at 55–60 °C and 30 s at 72 °C) and a final
elongation (5 min at 72 °C). The PCR products were separated by
electrophoresis on 2% agarose gel containing 0.01% of ethidium
bromide and photographed under UV irradiation at 320 nm.
2.3. Artery tension recording
The human umbilical artery rings were placed in an organ
bath (LE01.004, Letica) containing Krebs–bicarbonate solution
(composition in mM: NaCl 119, KCl 5.0, NaHCO3 25, KH2PO4
1.2, CaCl2 0.5,MgSO4 1.2, EDTA 0.03, Glucose 11) at 37 °C and
continuously gassed with carbogen. The artery rings were sus-
pended by two parallel stainless steel wires and tension mea-
surement was performed using isometric transducers (TRI201,
Panlab, Spain), amplifier (ML118/D Quad Bridge, ADInstru-
ments), interface PowerLab/4SP (ML750, ADInstruments) and
computerised systemwith Chart5 PowerLab software (ADInstru-
ments). During the resting periods, the organ bath solution was
changed every 15 min. Initially, the rings were equilibrated for
60 min until a resting tension of 1 g was achieved. After this, the
rings were challenged with 5-HT (1 μM) to test their viability.
Rings that induced contraction lower than 1 g when challenged
with 5-HT were excluded from the study. Afterwards, the rings
were contracted using histamine (10 μM) or 5-HT (1 μM) and the
role of PDE isoforms in cyclic nucleotidemediated vasodilatation
was evaluated using different PDE inhibitors. 3-isobutyl-1-
methylxanthine (IBMX, 50 μM) was used as a broad-spectrum
PDE inhibitor. A 20 μM concentration of 8-methoxymethyl-3-
isobutyl-1-methylxantine (MIBMX) was employed to selectively
inhibit PDE1. To selective inhibit PDE3 cilostamide 1 μM was
utilised. Rolipram 1 μMwas used to selective inhibit PDE4. The
selective inhibition of PDE5 was obtained using dipyridamole
3 μM or T0156 1 μM.
The effects of forskolin (adenylate cyclase stimulator) and
sodium nitroprusside (SNP; guanylate cyclase stimulator) on 5-
HT- and histamine-contracted human umbilical arteries were
also studied. The effects of these cyclases stimulators were also
analysed in presence of several PDE inhibitors to determine the
role of these enzymes in the control of the cAMP and cGMP
levels.
2.4. Drugs and chemicals
All drugs and chemicals were purchased from Sigma-
Aldrich Quimica (Sintra, Portugal), except forskolin, rolipram,
T0156 and ciclostamide, which were purchased from Biogen
Cientifica (Madrid, Spain). Forskolin, rolipram, IBMX, dipyr-
idamole, MIBMX and ciclostamide were initially dissolved in
ethanol. Histamine, 5-HT and SNP were initially dissolved in
Fig. 2. Relaxation induced by PDE inhibitors on histamine-contracted arteries.
The percent of inhibition induced by IBMX (50 μM), MIBMX (20 μM),
cilostamide (CIL, 1 μM), rolipram (ROL, 1 μM), dipyridamole (DIP, 3 μM) and
T0156 (1 μM) on the histamine (10 μM) effect is shown. The bars represent the
means and the lines the S.E.M. of the numbers of experiments indicated near the
bars. Statistical significant differences versus IBMX effect was performed using
one-way ANOVA with Dunnet's post hoc test (Pb0.05).
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Krebs solution. The final concentration of ethanol in the organ
bath did not exceed 0.1%.
2.5. Statistical analysis
Statistical analysis of the data was performed using the
SigmaStat Statistical Analysis System, version 1.00 (1992).
Results were expressed as mean±S.E.M. of n experiments.
Comparison among multiple groups was analysed by using a
one-way ANOVA followed by Dunnet's post hoc test to
determine significant differences among the means. Probability
levels lower than 5% were considered significant (Pb0.05).
3. Results
3.1. Expression of PDE in human umbilical artery
Semi-quantitative RT-PCR analysis using specific primers
for several human PDE genes was performed in human um-
bilical artery smooth muscle layers in order to check for the
expression of PDE1 (A and B), PDE2A, PDE3 (A and B),
PDE4 (A, B, C and D) PDE5A and PDE7 (A1 and A2). Positive
controls were performed using glyceraldehyde 3-phosphate
dehydrogenase primers (GAPDH) (Fig. 1). Negative controls
were performed in the absence of cDNA with the primers
used in these studies (data not shown). Human umbilical artery
smooth muscle expresses significant amounts of four families:
PDE1, PDE3, PDE4 and PDE5, concretely the products of the
PDE1B, PDE3A, PDE3B, PDE4C, PDE4D and PDE5A genes
(Fig. 1). Concerning PDE5A, two products with different size of
PDE5A were amplified indicating the existence of two splice
variants (Fig. 1). Expression of products from PDE2 and PDE7
families was not detected.Fig. 1. Expression analysis of different phosphodiesterase (PDE) subtypes.
Reverse transcriptase PCR analysis was performed using mRNA from human
umbilical artery smooth muscle layers. The PCR products were analyzed on a
2.0% agarose gel and pictures of the ethidium bromide stained gels are shown.
The PCR primers used for this analysis and expected length of the PCR products
are described in Methods. Positive (Gp) and negative (Gn) controls were
performed using glyceraldehyde 3-phosphate dehydrogenase primers. The
expression of PDE1A (1A), PDE1B (1B), PDE2A (2A), PDE3A (3A), PDE3B
(3B), PDE4A (4A), PDE4B (4B), PDE4C (4C), PDE4D (4D), PDE5A (5A),
PDE7A1 (7A1) and PDE7A2 (7A2) was analysed. Positions of molecular
weight markers are indicated in base pairs (Bp).3.2. Effect of PDE inhibition and cyclases stimulation on
histamine-contracted arteries
Human umbilical artery rings without endothelium were
contracted by histamine (10 μM) and 5-HT (1 μM) and the
effect of several PDE inhibitors on these contractions was
analysed. Steady contractions were attained after 5–10 min in
presence of 5-HT (1 μM) or histamine (10 μM) and the tension
obtained was 1794.8±71.7 and 1292.0±61.8 mg respectively,
which were significantly different (Pb0.05). Concerning the
drugs stimulating the cyclases or inhibiting the PDEs, the time
to reach the relaxing effects for each concentration was between
4 and 15 min. The application of IBMX relaxed histamine-
contracted arteries on 47.4±7.2% indicating the effect of the
inhibition of all PDE types (Fig. 2). This effect seems to be
mainly due to PDE4 and PDE5 inhibition because only rolipramFig. 3. Relaxation induced by adenylate cyclase stimulation in presence and
absence of PDE inhibitors on histamine-contracted arteries. The percent
relaxation induced by forskolin (FSK, 10 μM) alone or in presence of IBMX
(50 μM), MIBMX (20 μM), cilostamide (CIL, 1 μM) or rolipram (ROL, 1 μM)
on histamine (10 μM) effect is shown. The bars represent the means and the lines
the S.E.M. of the numbers of experiments indicated near the bars. Statistical
significant differences versus FSK effect was performed using one-way ANOVA
with Dunnet's post hoc test (Pb0.05).
Fig. 4. Original record of two tension experiments with human umbilical artery
rings. A) The artery rings were contracted by histamine (10 μM) and relaxed by
rolipram (1 μM) alone and in presence of forskolin (10 μM); B) The artery rings
were contracted by 5-HT (1 μM) and relaxed by T0156 (1 μM) alone and in
presence of SNP (10 μM).
Fig. 6. Relaxation induced by PDE inhibitors on 5-HT contracted arteries. The
percent of inhibition induced by IBMX (50 μM), MIBMX (20 μM), cilostamide
(CIL, 1 μM), rolipram (ROL, 1 μM), dipyridamole (DIP, 3 μM) and T0156
(1 μM) on the 5-HT (1 μM) effect is shown. The bars represent the means and
the lines the S.E.M. of the numbers of experiments indicated near the bars.
Statistical significant differences versus IBMX effect was performed using one-
way ANOVA with Dunnet's post hoc test (Pb0.05).
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2.8%) induced effects comparable to that of IBMX (Fig. 2). The
relaxation induced by MIBMX and cilostamide on histamine-
contracted arteries was significantly lower than the observed
with IBMX (Pb0.05). Ethanol, the vehicle used to dissolve the
PDE inhibitors did not have any effect at the concentrations
used (data not shown).Fig. 5. Relaxation induced by guanylate cyclase stimulation in presence and
absence of PDE inhibitors on histamine-contracted arteries. The percent
relaxation induced by SNP (10 μM) alone or in presence of MIBMX (20 μM),
cilostamide (CIL, 1 μM), dipyridamole (DIP, 3 μM) or T0156 (1 μM) on
histamine (10 μM) effect is shown. The bars represent the means and the lines the
S.E.M. of the numbers of experiments indicated near the bars. Statistical
significant differences versus SNP effect was performed using one-way ANOVA
with Dunnet's post hoc test (Pb0.05).When forskolin was used to increase cAMP levels, this
adenylate cyclase activator relaxed 43.6±8.9% the histamine-
induced contraction (Fig. 3). The inhibitors of PDEs degrading
cAMP were further added to forskolin. Only IBMX and
rolipram significantly increased the forskolin effect (Pb
0.05) and almost completely relaxed the human umbilical ar-
tery (92.5±4.9% and 90.9±4.7%, respectively). PDE1 and
PDE3 inhibitors did not increase the forskolin effect on hista-
mine contraction (PN0.05) (Fig. 3). Fig. 4A shows a record
of an experiment in which histamine-contracted arteries were
relaxed by rolipram and this effect is increased when forskolin
is further added.
When SNP was used to increase cGMP levels, this guanylate
cyclase activator induced a relaxation of 39.8±10.1% on the
histamine contraction. The inhibitors of PDEs degrading cGMP
were further added and only the PDE5 selective inhibitors
(dipyridamole and T0156) increase significantly (Pb0.05) theFig. 7. Relaxation induced by adenylate cyclase stimulation in presence and
absence of PDE inhibitors on 5-HT contracted arteries. The percent relaxation
induced by forskolin (FSK, 10 μM) alone or in presence of IBMX (50 μM),
MIBMX (20 μM), cilostamide (CIL, 1 μM) or rolipram (ROL, 1 μM) on 5-HT
(1 μM) effect is shown. The bars represent the means and the lines the S.E.M. of
the numbers of experiments indicated near the bars. Statistical significant
differences versus FSK effect was performed using one-way ANOVA with
Dunnet's post hoc test (Pb0.05).
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significantly increase the SNP effect on histamine-contracted
arteries (PN0.05).
3.3. Effect of PDE inhibition and cyclases stimulation on 5-HT
contracted arteries
Our results demonstrated the existence of a lower relaxing
effect of the PDE inhibitors on 5-HT contracted arteries, even
in the presence of forskolin or SNP (Figs. 6, 7 and 8). The
application of IBMX relaxed 5-HT contracted human umbili-
cal artery on 8.2±1.5% (Fig. 6). Only PDE5 inhibition by
dipyridamole or T0156 elicited similar effects than that of
IBMX (PN0.05). As showed in the Fig. 6, the effects induced
by MIBMX, cilostamide and rolipram on 5-HT contracted
arteries were weak and significantly lower than that observed
with IBMX (Pb0.05). Ethanol, the vehicle used to dissolve the
PDE inhibitors did not have any effect at the concentrations
used (data not shown).
The activation of adenylate cyclase by forskolin relaxed 5-
HT contracted human umbilical artery in 3.9±1.4%. When
inhibitors of PDEs hydrolysing cAMP were added, the forskolin
effect was only significantly increased by IBMX (17.7±1.5%)
and rolipram (10.0±1.5%) (Pb0.05) (Fig. 7). Like previously
shown for histamine-contracted arteries, PDE1 and PDE3
inhibitors did not increase the forskolin effect (PN0.05) on 5-
HT contracted arteries (PN0.05).
The relaxing effect of SNP on 5-HT contracted human
umbilical artery was 23.3±4.8% (Fig. 8). Concerning the PDEs
specifically degrading cGMP, the SNP relaxing effect was
only significantly augmented in the presence of the PDE5
inhibitor T0156 (52.0±7.0%) (Pb0.05). Fig. 4B shows a record
of an experiment in which 5-HT contracted arteries are relaxed
by T0156 and this effect is increased when SNP is further
added.Fig. 8. Relaxation induced by guanylate cyclase stimulation in presence and
absence of PDE inhibitors on 5-HT contracted arteries. The percent relaxation
induced by SNP (10 μM) alone or in presence of MIBMX (20 μM), cilostamide
(CIL, 1 μM), dipyridamole (DIP, 3 μM) or T0156 (1 μM) on 5-HT (1 μM) effect
is shown. The bars represent the means and the lines the S.E.M. of the numbers
of experiments indicated near the bars. Statistical significant differences versus
SNP effect was performed using one-way ANOVAwith Dunnet's post hoc test
(Pb0.05).4. Discussion
The present study investigates the involvement of different
PDE families in the relaxation mediated by the cyclic nucle-
otides in human umbilical artery. The precise regulation of the
intracellular levels of cAMP and cGMP plays an important
role in many physiological processes, including vascular smooth
muscle contractility (Matsumoto et al., 2003). As cyclic nu-
cleotides can modulate the vascular smooth muscle tone, the
PDEs have become an attractive target for drug development,
due to the existence of different PDE isozymes which are dif-
ferently regulated and distinctly expressed in the cardiovascular
system. Concerning the fetoplacental circulation, cyclic nucleo-
tide increase was appointed as inducing vasodilatation (Amit
et al., 1998; Downing et al., 2004), however the PDE types
modulating this effect were not described yet.
Several authors have reported that forskolin, a direct
stimulator of adenylate cyclase, induced relaxation of different
arteries such as canine colonic artery (Barnette et al., 1993),
human dorsal artery (Segarra et al., 2002), human pulmonary
artery (Rabe et al., 1994) and human placental vessels (Figueroa
et al., 2000). These findings suggest that the elevation of cAMP
plays a functional role in the regulation of vascular smooth
muscle tone. Our results also showed that forskolin induces
relaxation of contracted human umbilical arteries, and the effect
of this adenylate cyclase stimulator on histamine-contracted
arteries was bigger than on 5-HT contracted arteries. The dif-
ferent receptors implicated in the contractile effect of these
agents could explain these results. The contractile effect of 5-
HT in denuded human umbilical artery seems to be due to the
activation of two receptors: 5-HT1B which activation inhibits
adenylate cyclase; and 5-HT2A which activation increases ino-
sitol 1,4,5-triphosphate (IP3) levels (Lovren et al., 1999). The
contraction of human umbilical artery induced by histamine is
due to the activation of H1 receptors, which induces increase of
IP3 levels (Hawley et al., 1995). However, the expression of H2
receptors in human umbilical smooth muscle cells was also
reported (Schneider et al., 2004) and the activation of these
receptors stimulates adenylate cyclase. Thus, histamine and 5-
HT can increase IP3 levels, but histamine can also increase
cAMP basal levels meanwhile 5-HT could have the opposite
effect and this could be the cause of the lower relaxant effect of
forskolin on 5-HT contracted arteries.
Sodium nitroprusside, a guanylate cyclase stimulator, induced
relaxation of contracted human umbilical arteries, indicating that
the elevation of intracellular cGMP plays a functional role in the
regulation of vascular smooth muscle tone. The vasodilator ef-
fects of cGMP increase are bigger that the cAMP increase in 5-
HT contracted arteries (Figs. 7 and 8) indicating that the cGMP
pathway is more efficient relaxing the 5-HT-induced contrac-
tions. The lower relaxing efficiency of cAMP on 5-HTcontracted
arteries could be due to the activation of 5-HT1B receptors which
activation inhibits adenylate cyclase. Other authors also ob-
served the vasodilator properties of cGMP in canine colonic artery
(Barnette et al., 1993), human pulmonary artery (Rabe et al.,
1994), human placental vessels (Figueroa et al., 2000) and human
umbilical artery (Lovren and Triggle, 2000). Furthermore, Amit
108 A.J. Santos-Silva et al. / European Journal of Pharmacology 582 (2008) 102–109et al. demonstrated that sublingual administration of isosorbide
dinitrate, a nitrovasodilator, reduced maternal blood pressure and
uterine arterial resistance (Amit et al., 1998). Our results also
showed that SNP-induced relaxation on histamine-contracted
arteries was bigger than on 5-HT contracted arteries. Lovren and
Tiggle also observed that SNP induced relaxation was lower in
human umbilical artery contracted with 5-HT when compared
with arteries contracted with a thromboxane analogue (Lovren
and Triggle, 2000).
The enzymes degrading cyclic nucleotides are the PDEs and
the study of the isoforms that regulate cyclic nucleotide de-
pendent vascular effects is crucial to analyze potential uses of
the PDE inhibitors in therapeutics. Earlier studies using distinct
vascular samples have provided direct or indirect evidence for
the presence of products of six different PDE families in the
vascular smooth muscle. The PDE1 (A and B) isoforms were
detected in the smooth muscle isolated from the medial layer of
human aorta (Rybalkin et al., 1997). PDE2 transcripts are not
present in the human vascular smooth muscle and, at the vas-
cular smooth muscle level, were only detected in porcine aorta
smooth muscle (Matsumoto et al., 2003). The PDE3 expression
was noticed in several human blood vessels, including placental
smooth muscle (Omori and Kotera, 2007). PDE4 expression
was observed in human pulmonary, mesenteric and femoral
arteries (Maurice et al., 2003). PDE5 transcripts were detected
in various human vascular tissues (Omori and Kotera, 2007).
PDE7 was observed in human pulmonary artery and in endo-
thelial cells (Matsumoto et al., 2003). Our results in human
umbilical artery smooth muscle demonstrated the presence of
transcripts encoding products from the following subtypes:
PDE1B, PDE3A, PDE3B, PDE4C, PDE4D and PDE5A. It is
interesting to note that two PCR products were obtained for
PDE5A. Two alternate exons are present in the N-terminal
region amplified giving the possibility of expressing different
products with similar size like the ones obtained in our experi-
ments: the smaller containing 140 base pairs and the bigger with
320 base pairs (Lin et al., 2006). Thus, the expression of pro-
ducts from four PDE families was detected in the human um-
bilical artery smooth muscle.
The use of a broad-spectrumPDE inhibitor (IBMX) resulted in
a clear reduction in the histamine-induced contractility on human
umbilical artery. The IBMX effect on 5-HT contracted arteries
was almost five times lower than on histamine-contracted arteries.
As already suggested before, these differences can be due to the
different pathways implicated in the activation of histamine and 5-
HT receptors. To analyse the functionality of the PDE types in the
regulation of the contractility of human umbilical artery, selective
inhibitors of the PDE families expressed in this artery were used.
Because at themicromolar concentrations the PDE5 inhibitors are
not specific, two different inhibitors were used. T0156 inhibits
PDE5 and PDE6 (Mochida et al., 2002b).Dipyridamol can inhibit
PDE5, PDE6, PDE8 and PDE10 (Hetman et al., 2000) and can
also inhibit the adenosine transport (Rubin et al., 2000). Rolipram,
dipyridamole and T0156, but not MIBMX nor cilostamide, re-
laxed histamine-contracted human umbilical artery in a similar
degree than IBMX. The relaxant effect of dipyridamole and
T0156 on 5-HT-induced contraction was also similar than thatobtained with IBMX. These results suggest a main role of PDE4
and PDE5 in the modulation of the cyclic nucleotide dependent
relaxation.
The sequential addition of forskolin and inhibitors of the
PDE families degrading cAMP allowed the study of the role of
these isoforms on the cAMP-dependent relaxation of human
umbilical artery. The addition of IBMX or rolipram to forskolin
increased the effect of the adenylate cyclase stimulator and
almost completely relaxed the human umbilical artery con-
tracted by histamine. This suggests that PDE4 is the key PDE
regulating the cAMP-dependent relaxation. Even if the relaxant
effects are lesser, the results obtained with 5-HT contracted
arteries confirmed the importance of PDE4 in the regulation of
human umbilical artery smooth muscle contractility, because
only rolipram and IBMX significantly increased the forskolin
vasodilator effect. Some authors suggested that PDE4 is the
predominant family implicated in the cAMP-dependent regula-
tion of canine basilar artery contractility (Willette et al., 1997).
Other authors, using human cavernous arteries contracted with
norepinephrine, observed that cAMP-dependent relaxation is
regulated by PDE4 and PDE3 (Waldkirch et al., 2005).
The sequential addition of SNP, a NO donor, and inhibitors
of the PDE families degrading cGMP allowed the study of the
role of these isoforms on the cGMP-dependent relaxation of
human umbilical artery. Further addition of selective PDE5
inhibitors (dipyridamole or T0156) to SNP revealed a signifi-
cant increase in the relaxation of histamine-contracted arteries,
an effect that was not observed with PDE1 or PDE3 inhibitors.
These data suggest that PDE5 is involved in the regulation of
the relaxation associated to cGMP. Is well known that NO
stimulates cGMP formation by activation of soluble guanylate
cyclase, which in turn has vasodilatatory actions (Kristek et al.,
2007). In this context, the NO/cGMP pathway was involved in
human umbilical artery vasodilatation (Lovren and Triggle,
2000). The data obtained with 5-HT contracted rings also con-
firmed the major role of PDE5 modulating cGMP-dependent
vasodilatation, because dipyridamole and T0156 were the
unique PDE inhibitors that increased the SNP relaxing effect.
These data also shows that the vasodilator effects of the com-
bination of SNP and T0156 are bigger than that induced by the
mixture of forskolin and rolipram (Figs. 7 and 8), confirming
that the 5-HT-induced contractions are more efficiently relaxed
by the cGMP pathway. The involvement of PDE5 in the modu-
lation of cGMP-dependent relaxation was also observed by
Rabe et al. (1994) in human pulmonary artery contracted with
prostaglandin F2α, although this authors also proposed a role of
the PDE3 in this action (Rabe et al., 1994). Waldkirch et al.
(2005), working with human cavernous arteries contracted by
norepinephrine, implicated PDE5 in the regulation of the
vasodilatation associated to cGMP (Waldkirch et al., 2005).
Some authors proposed the use of nitrovasodilators or PDE5
inhibitors for pregnant women with vascular complications
(Amit et al., 1998; Downing et al., 2004; Pinheiro da Costa et al.,
2006).
In summary, our results demonstrate that the increase of
cAMP and/or cGMP levels in the human umbilical vascular
smooth muscle induces relaxation. Four families of PDE are
109A.J. Santos-Silva et al. / European Journal of Pharmacology 582 (2008) 102–109expressed in this smooth muscle: PDE1, PDE3, PDE4 and
PDE5. Between these families, PDE4 and PDE5 are the key
enzymes involved in the regulation of human umbilical artery
relaxation associated to cAMP and cGMP, respectively. PDE1
and PDE3 activities seem to be not relevant to this regulation.
Our results suggest that, due to the functional importance of
these PDE isozymes, the selective PDE4 and PDE5 inhibitors
may represent a therapeutic tool for the treatment of some
pathologies as pre-eclampsia and hypertension in pregnancy.
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